当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
John D Andrew, Abdul A Hathi, Lino Steffy and Manjula Devi
Bipolar disorder is a chronic neurological disorder. It is the 6th major ailment which affect 1% of the world population. Lithium is the only classic drug available because the molecular mechanisms of remain unclear. It is difficult to establish in vitro adequate models for pathological analysis because of the heterogeneity of this disorders. The active principle of herbal preparations like ginseng, ephedra sinica, Brindle berry, clove etc. are able to decrease the symptoms of bipolar disorder. Zebrafish and human share 71% of the same genes and 82% of genes associated with human diseases and rapid development and easy to handle. Due to this fact scientist improved the usage of Zebrafish in preclinical screening, as a prominent model in drug discovery and development for neurological disorders. Different procedures are available to study the stress or depression level. They are highly sensitive to psychotropic drugs and different methods like novel tank test, light and dark box method, cognitive model, social model and net stress model are some of the behavioral models performed on Zebrafish. Our work summarizes the growing utility of Zebrafish in pharmacy research and its benefits to overcome the hurdles in the discovery of drugs for neurological disorders.